COBRE Center for Antimicrobial Resistance and Therapeutic Discovery
Developing a Better Understanding and Novel Approaches to Antimicrobial Resistance
The COBRE Center for Antimicrobial Resistance and Therapeutic Discover (CARTD) at The Miriam Hospital enables and supports research to better understand the mechanisms of antimicrobial resistance and develop countermeasures.
Contact Us
For more information about the COBRE Center for Antimicrobial Resistance and Therapeutic Discovery (CARTD), contact:
Erika D'Agata, COBRE Director, at [email protected] or
Susan Johnson, Administrative Coordinator, at [email protected]
An Urgent Public Health Threat
In the US, more than 2.8 million antimicrobial-resistant infections occur each year. More than 35,000 people die as a result, according to CDC’s 2019 Antibiotic Resistance (AR) Threats Report. The estimated national cost to treat infections caused by germs frequently found in health care can be more than $4.6 billion annually. Worldwide, antimicrobial resistance kills at least 1.27 million people and was associated with nearly 5 million deaths in 2019. The CARTD program at The Miriam Hospital is one of just two COBRE (Center of Biomedical Research Excellence) research centers, out of more than 120, in the US that are nationally focused on antimicrobial resistance.
Research and Clinical Trials
Learn more about the innovative infection research and clinical trials currently being conducted at Lifespan.